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Abstract
Sequence-based typing (SBT) is one of the most comprehensive methods utilized for HLA typing.
However, one of the inherent problems with this typing method is the interpretation of ambiguous
allele combinations which occur when two or more different allele combinations produce identical
sequences. The purpose of this study is to investigate the probability of this occurrence. We
performed HLA-A,-B SBT for Exons 2 and 3 on 676 donors. Samples were analyzed with a capillary
sequencer. The racial distribution of the donors was as follows: 615-Caucasian, 13-Asian, 23-
African American, 17-Hispanic and 8-Unknown. 672 donors were analyzed for HLA-A locus
ambiguities and 666 donors were analyzed for HLA-B locus ambiguities. At the HLA-A locus a total
of 548 total ambiguous allele combinations were identified (548/1344 = 41%). Most (278/548 =
51%) of these ambiguities were due to the fact that Exon 4 analysis was not performed. At the HLA-
B locus 322 total ambiguous allele combinations were found (322/1332 = 24%). The HLA-B*07/08/
15/27/35/44 antigens, common in Caucasians, produced a large portion of the ambiguities (279/322
= 87%). A large portion of HLA-A and B ambiguous allele combinations can be addressed by
utilizing a group-specific primary amplification approach to produce an unambiguous homozygous
sequence. Therefore, although the prevalence of ambiguous allele combinations is high, if the
resolution of these ambiguities is clinically warranted, methods exist to compensate for this
problem.
Introduction
The precise identification of HLA Class I and Class II alle-
les is critical for successful hematopoietic progenitor
transplants, the development of peptide based viral and
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cancer vaccines, and investigating immune response [1,2].
DNA sequencing is one of the most comprehensive meth-
ods available for HLA typing. Sequence-based typing
(SBT) involves PCR amplification of specific coding
regions of HLA genes and sequencing of the amplicons
[3,4]. SBT allows for a detailed interpretation of HLA alle-
les by comparing nucleotide sequences of the polymor-
phic, and sometimes conserved, regions of the HLA gene
to a database of possible allelic combinations. While SBT
permits the highest resolution of genotypes, like all typing
methods, it has limitations. One of the inherent problems
when using SBT is the interpretation of ambiguous allele
combinations which can occur for several reasons [5-7].
There exist two main types of ambiguous typing results
obtained with SBT. The first is when a heterozygous
sequence can be explained by more than one possible pair
of alleles within the region analyzed. The second exists
when alleles are defined by a polymorphism outside the
region analyzed. In addition to these two situations, a
third type of ambiguity arises when an allele has an
incomplete sequence in the region analyzed.
The prevalence of ambiguities in HLA typing relates to the
nature of polymorphisms which exists in the sequence of
the major histocompatibility complex (MHC) Class I and
Class II genes. The majority of polymorphisms that distin-
guish one MHC allele from another are oftentimes due to
gene conversion, recombination and exon shuffling
events. Due to this, polymorphic motifs at given positions
are generally shared among several alleles.
Sequence-based typing involves PCR amplification and
sequencing of specific HLA exons, which are known to be
polymorphic, from genomic DNA. For each HLA locus
both alleles are amplified and sequenced; therefore, it is
not always possible to determine exactly which two alleles
were responsible for sequence results. For example two or
more different allele combinations can combine to pro-
duce identical sequences due to the heterozygous base
pair combinations, the first type of ambiguity. More spe-
cifically, in the Class I region, HLA-B*070201, 3503
would have the same nucleotide sequence as HLA-
B*0724, 3533 in positions 559 and 560 (Figure 1). In this
example, the SBT produces a heterozygous base pair com-
bination at positions 559 and 560 with an international
union of biochemists (IUB) designation of
K(G+C)W(A+T). Therefore, the interpretation to the high
resolution level can not be made because it is not known
which allele combination is correct.
The second type of ambiguity relates to defining a poly-
morphism outside the region analyzed. For example,
many HLA-A alleles are defined by a polymorphism
located in Exon 4 (Table 3). Traditionally, for Class I
typing most laboratories only sequence Exon 2 and Exon
3; for Class II typing most laboratories only sequence
Exon 2. This approach has been the standard due to the
functional relevance of this region which defines the pep-
tide groove of Class I and Class II molecules, respectively.
However, some Class I alleles have identical sequences
across Exons 2 and 3. To resolve these alleles it is necessary
to analyze the gene at the region where they differ. As
DNA sequencing has become easier and more widely
applied to defining HLA alleles, additional
polymorphisms have been found in other exons, and also
in the introns.
Finally, an ambiguity may be due to incomplete sequence
information, because not all alleles have been sequenced
for the same exons. For some alleles the entire sequence is
not known in the region that is amplified. For example,
A*010101 has been sequenced from Exon 1 through Exon
8, but A*010102 has been sequenced only in Exon 2 and
Exon 3. Numerous ambiguities arise due to an incomplete
sequence in Exon 4. The minimum requirements for sub-
mission of new sequences into reference databases of HLA
sequences are the sequencing of Exon 2 and Exon 3 for
Class I and Exon 2 for Class II.
The relevance of completely identifying the polymor-
phisms found by SBT needs consideration. In clinical
respects, it may not always be necessary to resolve ambi-
guities that involve a silent non-coding polymorphism
and/or an intron polymorphism. Exceptions will exist to
this situation where the polymorphism negates or impairs
expression (e.g. A*24020102L or B*15010102N – both
are due to an intron polymorphism). However, for inves-
Two different HLA-B allele combinations that yield identical  sequence based-typing results Figure 1
Two different HLA-B allele combinations that yield identical 
sequence based-typing results. The amplification and 
sequencing of exon 3 of HLA Class I from a HLA-B*070201/
B*0724 subject and a HLA-B*3503/3533 subject produce the 
same results. Both G and C are detected at nucleotide 559 
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tigations of genetic inheritance or disease association, the
definition of all polymorphisms may be significant.
The purpose of this study was to summarize the incidence,
nature, and cause of ambiguous HLA SBT results. This rep-
resents an important step toward developing strategies to
reduce or eliminate this problem.
Methods
DNA Isolation
Genomic DNA was isolated from peripheral blood using
the Gentra PUREGENE® isolation kit (Gentra Systems,
Minneapolis, MN, U.S.A). The DNA was resuspended in
Tris HCl buffer (pH 8.5) and the concentration was meas-
ured using a Pharmacia Gene Quant II Spectrophotome-
ter. The DNA was then stored at -70°C until testing.
Sequence-Based Typing
The primary PCR amplification reaction consists of a 1.5
kb reaction encompassing exon 1 through intron 3 of the
HLA region. All reagents necessary for primary amplifica-
tion and sequencing are supplied in the HLA-A or HLA-B
AlleleSEQR Sequenced Based Typing Kits (Forensic Ana-
lytical, Hayward, CA, U.S.A.). The primary amplification
PCR products were purified from excess primers, dNTPs,
and genomic DNA using ExoSAP-IT (Amersham Life Sci-
ence, Cleveland, OH, U.S.A.) Each template was
sequenced in the forward and reverse sequence orienta-
tion for exon 2 and Exon 3 according to protocols sup-
plied with the SBT kit. Excess dye terminators were
removed from the sequencing products utilizing an etha-
nol precipitation method with absolute ethanol. The reac-
tion products were reconstituted with 15 µl of Hi-Di™
Formamide (PE Applied Biosystems/Perkin-Elmer, Foster
City, CA, U.S.A.) and analyzed on the ABI Prism® 3700
DNA Analyzer with Dye Set file: Z and mobility file:
DT3700POP6 {ET}.
Results
Sequence based typing analysis of HLA-A and B alleles was
performed on a population of 676 normal donors. The
racial distribution of the subjects studied was: 615 Cauca-
sian, 13 Asian, 23 African American, 17 Hispanic and 8
Unknown. 672 of the 676 subjects were analyzed for the
Table 1: Prevalence of ambiguous sequence-based typing allele combinations among 672 people analyzed at the HLA-A locus and 666 
analyzed at the HLA-B locus
Allele Occurrence Allele Occurrence
A*01 174 B*07 51
A*02 162 B*08 56
A*03 43 B*13 2
A*23 2 B*14 3
A*24 104 B*15 26
A*25 5 B*18 17
A*26 26 B*27 37
A*29 3 B*35 34
A*31 4 B*39 3
A*32 5 B*40 31
A*66 1 B*44 44
A*68 16 B*51 14
A*74 3 B*52 1
B*55 2
B*58 1
TOTAL 548 TOTAL 322
Table 2: Nature and Resolution of HLA-A and -B Allele Ambiguities
HLA-A Locus HLA-B Locus
Portion of alleles with ambiguities 41% 24%
Most frequently involved alleles A*01, 02, and 24 B*7, 8, 15, 35, and 44
Methods used to resolve ambiguities Exon 4 sequencing (51%) Many different methods
A*02 subtyping (30%)Journal of Translational Medicine 2004, 2:30 http://www.translational-medicine.com/content/2/1/30
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presence of HLA-A locus ambiguities and 666 were ana-
lyzed for HLA-B locus ambiguities. Each allele was
counted separately in this analysis in order to determine
the total percentage of ambiguous allele combinations.
Four new potential alleles were found.
At the HLA-A locus a total of 548 ambiguous allele com-
binations were found. This represented 41% of all HLA-A
alleles (548 of 1344) (Table 1). Approximately half, 51%
(278 of 548) of these ambiguities were due to the fact that
Exon 4 analysis was not performed (Table 2 and Table 3).
HLA-A*01 and HLA-A*24 are very prevalent alleles and
most ambiguities involving these alleles could be resolved
by performing Exon 4 analysis. For example the ambiguity
most prevalent for HLA-A*01 in this study was HLA-
A*0101/0104N. The sequences of these two alleles are
identical across Exons 2 and 3; the difference between
these two alleles occurs at position 627insC, which is
located in Exon 4.
A large portion of HLA-A locus sequence-based typing
ambiguities involved HLA-A*02, 30% or 162 of 548.
Some of the HLA-A*02 ambiguities can also be resolved
via Exon 4 sequencing and most of the other HLA-A*02
ambiguities can be resolved with traditional A*02
molecular subtyping methodologies using sequence spe-
cific primers or sequence specific probes.
Not all HLA-A ambiguous allele combinations can be
resolved as simply as those involving A*01, A*024 and
A*02. Most of the remaining 19% (108 of 548) of the
HLA-A ambiguities cannot be resolved with Exon 4 analy-
sis (Table 3).
Review of the HLA-B locus results revealed 322 ambigu-
ous allele combinations among the 1332 total HLA-B alle-
les (24%). Antigens HLA-B*07/08/15/27/35/44,
common in Caucasians, produced the largest portion of
the ambiguities (279 of 322 or 87%). Each of these ambi-
guities had an independent reason for occurring. Table 4
lists some of the more common B locus ambiguities seen
in this study. The reason for each ambiguity is variable;
however a large portion of the ambiguities are related to
cis/trans allele combinations.
Discussion
While SBT provides the best available typing of HLA-A
and B antigens, it is limited by sequence results that don't
allow the precise identification of alleles. We found that
41% of HLA-A alleles and 24% of HLA-B alleles were
ambiguously typed. The ambiguities involve some of the
most frequent HLA-A and HLA-B antigens: A*01, A*02,
A*24, B*07, B*08, B*15, B*27, B*35, and B*44.
However, ambiguous allele combinations occur in all loci
tested in HLA. The IMGT/HLA Sequence Database http://
www.ebi.ac.uk/imgt/hla/ maintains an updated listing of
Table 3: Specific A locus sequence-based typing ambiguities discovered during this study and the reason that the ambiguity occurs.
1 A*010101/04N 0104N is resolved as a C insertion at bp 628 in exon 4.
2 A*2402/09N/11N 24020101 is unresolvable from 24020102L. 2409N is resolved in exon 4 at bp 742 by a T 
substitution. The base change responsible for 2409N creates a premature termination on 
exon 4. 2411N is the result of the same insertion at 0104N.
3 A*010101/04N, 0201/09/43N or 0236, 3604 0209 is resolved as an A substitution in exon 4 at bp 779. 0243N is resolved as a C insertion 
at bp 780. 0236 and 3604 are not defined in exon 4.
4 A*020101/43N, 030101 or 0226, 0307 or 0234, 
0308
0226 and 0308 are not defined in exon 4. As a result resolution can not be determined.
5 A*0201/09/43N, 2301/07N or 0236, 2304 The 02 alleles are resolved in exon 4 as described above. 2307 N is resolved by a C insert at 
bp 628 in exon 4. Neither 0236 nor 2304 are defined in exon 4.
6 A*020101/09/43N, 240201/09N/11N or 0212, 
2413 or 0236, 24031/33
The 02 and 24 alleles are resolved in exon 4 as described above. Alleles 2413 and 0236 are 
not defined in exon 4.
7 A*0201/09, 2501 or 0206, 2503 The 02 alleles are resolved in exon 4 as described above. 2503 is not defined in exon 2.
8 A*030101, 240201/09N/11N or 0308, 2407 The 24 alleles are resolved in exon 4 as described above. 0308 is not defined in exon 4.
9 A*030101/2501 or 0308/2502 or 3204/6601 0308, 2502, and 3204 are not defined in exon 4.
10 A*A*030101, 2601 or 0308, 2613 0308 and 2613 are not defined in exon 4.
11 A*240201/09N/11N, 2601 or 2406, 2608 The 24 alleles are resolved in exon 4 as described above. 2406 is undefined in exon 4.
12 A*240201/09N/11N, 2902 or 24031, 2903 The 24 alleles are resolved in exon 4 as described above. 24020101, 2902 and 240301, 2903 
are unresolved.
13 A*020101/09/20/43N, 310102/3102 3102 is not defined in exon 4.
14 A*240201/09N/11N, 3201 or 2432, 3203 Both 2432 and 3203 are not defined in exon 4.
15 A*240201/09N/11N, 680102/11N or 2406, 
6809 or 2407, 680301
680102 and 6811N are not resolvable. 2406 and 6809 are not defined in exon 4. Exon 4 
would resolve 24020101 from 2409N and 2411N. 24020101, 680102/11N is unresolvable 
from 2407, 680301.
16 A*2502, 7401 or 2502, 7402 or 3201, 6601 7402 is not defined in exon 4. 2502, 7401 is unresolvable from 3201, 6601.Journal of Translational Medicine 2004, 2:30 http://www.translational-medicine.com/content/2/1/30
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all ambiguous possibilities http://www.ebi.ac.uk/imgt/
hla/ambig.html[5,8].
The need to initiate additional testing to clarify ambigu-
ous allele combinations must consider whether it is prac-
tical to obtain the information and if the information is
useful and valuable. The clinical need for the highest res-
olution HLA typing possible is an important variable that
must be considered. When typing is performed for cancer
and viral vaccine development studies, high resolution
allele data may be necessary to determine if a subject has
an HLA type that is appropriate for a study. Utilization of
high resolution data may also have implications for
hematopoietic progenitor cell transplantation. Trans-
plants involving partially mismatched or unrelated
donor-recipient pairs require a higher resolution typing,
but those involving HLA identical siblings may not.
If it is necessary to resolve an ambiguous typing, a variety
of different methods can be used. If the ambiguity is due
to an allele that has not been completely sequenced or
because the ambiguity is outside the region amplified by
the SBT assay, the resolution is dependent on the nature
and complexity of the ambiguity. Traditionally, for Class
I sequencing purposes most laboratories have performed
Exon 2 and Exon 3 analysis alone and for Class II sequenc-
ing only Exon 2 analysis. Many of the ambiguities can be
resolved by sequencing Exon 4. In fact, in this study the
largest portion of the typing ambiguities can be resolved
by sequencing exon 4. However, many polymorphisms in
exon 4 have no functional significance, so it may not be
worthwhile resolving most ambiguities involving exon 4.
The requirement for the analysis of Exon 4 to reduce the
incidence of typing ambiguity has now been realized by
commercial kit manufacturers. Both Celera Diagnostics
(Alameda, CA) and Forensic Analytical/Atria Genetics
(South San Francisco, CA) now include reagents for anal-
ysis of exon 4 in the HLA-A and -B kits. As the use of SBT
increases, more data may become available from non-tra-
ditional exons in addition to those that have been tradi-
tionally sequenced and the number of ambiguities due to
unknown sequences will decrease.
If the ambiguity is due to an identical heterozygote
sequence, as shown in figure 1, the ambiguous allele com-
binations can sometimes be addressed by utilizing a
group-specific primary amplification approach. In this
approach each allele is amplified separately by using
group specific primers for the alleles in question. A
homologous sequence for each separate allele can then be
obtained by sequencing the product of the group specific
amplifications. Currently, there are commercially availa-
ble kits (Forensic Analytical, Hayward, CA) for group spe-
cific amplification of the B locus. These kits allow the
primary amplification of a specific group. Upon discovery
of a particular ambiguity, a group specific amplification is
done to separate out the allele pair. The resultant
sequence will be homozygous for each allele in question.
Another method, which will reduce the number of ambi-
guities in the B locus, is the utilization of a two tube group
amplification approach (DYNAL Biotech, Brown Deer,
WI). This method allows for resolution of ambiguities by
taking into account the cis/trans allele combinations
which result from simultaneous nucleotide incorporation
for DNA templates being sequenced. This method allows
for separation of ambiguities when the ambiguity has
arisen due to a cis/trans situation. Ambiguities utilizing
this method are reduced by 56%. (Table 4) Another
method for separation of alleles is Haploprep™. (Genovi-
sion, Philadelphia, PA). Haploprep™ physically separates
a diploid sample into its haploid components. Once the
haplotypes are separated, routine HLA typing methods
can be performed to determine the alleles. This laboratory
is currently conducting studies to determine the efficacy of
this product. Several of the remaining HLA loci ambigui-
ties can be managed utilizing in-house custom group spe-
cific primary amplification mixes.
Table 4: Comparison of B locus ambiguities seen with the 
standard single tube amplification sequence-based typing method 
utilized in this study and those expected to be seen when utilizing 
a new two tube sequence-based typing method.
Ambiguities using a single tube amplification
B*270502 or 270502/13 or 2713
B*070201, 0801 or 0705/06, 0807
B*070201, 1402 or 0726, 1403
B*0702, 150101 or 0707, 1507 or 0709, 1563
B*070201, 180101/17N or 0707, 1814 or 0726, 1813
B*07021, 400101/0102 or 0705/06, 4033
B*070201, 440201/19N/27 or 0720, 4416 or 0724, 4421
B*0801, 180101/17N or 0804, 1807 or 0812, 1814
B*0801, 400101/0102 or 0804, 4007
B*0801, 440201/19N/27 or 0802, 4409
B*150101/15, 3503/13
B*1503, 3501 or 1529, 3528
B*3501, 400101/0102 or 3520, 4007
B*350101/40N/42, 4402/19N/27 or 3510, 4412
B*400101, 4402 or 400102, 4402 or 4042, 4414
B*4001, 510101 or 4007, 5107
Ambiguities reduced by 56% if Two Tube Group 
Amplification is Used
Remaining ambiguities:
B*070201, 180101/17N or 0707, 1814 or 0726, 1813
B*070201, 440201/19N/27 or 0720, 4416 or 0724, 4421
B*0801, 180101/17N or 0804, 1807 or 0812, 1814
B*0801, 440201/19N/27 or 0802, 4409
B*150101/15, 3503/13
B*1503, 3501 or 1529, 3528
B*3501, 400101/0102 or 3520, 4007
B*400101, 4402 or 400102, 4402 or 4042, 4414
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Other methods which have been utilized to produce a
homologous sequence include cloning, reference strand
conformational analysis (RSCA), Pyrosequencing™ and
denaturing high-performance liquid chromatography
(DHPLC) [9-11]. Pyrosequencing™ is being explored by
this laboratory and results at this time are preliminary.
This method relies on the identification of a correct dis-
pensation order of nucleotides during the
Pyrosequencing™ process. Each ambiguity would require
a separate dispensation order to be determined due to the
unique nature of each ambiguity. The initial setup of this
technology may be cumbersome; however, once estab-
lished it may become very streamlined due to the availa-
bility of data on different ambiguous allele combinations.
Each one of these methods has advantages and concerns
which must be thoroughly investigated by the laboratory.
Some, not all, ambiguous allele combinations produced
by having identical heterozygote combinations can be
resolved utilizing traditional sequence specific primers
(SSP) or sequence specific oligonucleotide probes
(SSOP). This may be a more viable approach for laborato-
ries if they are already performing one of these
technologies.
In conclusion, although the prevalence of ambiguous
allele combinations is high, methods exist to compensate
for this problem. As the HLA field continues the discovery
of new alleles, alternative approaches to discerning
ambiguous allele combinations will need to be
investigated in order to reduce the ever-growing number
of ambiguities.
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